Factors associated with adherence to an end-of-study biopsy: Lessons from the prostate cancer prevention trial (SWOG-coordinated intergroup study S9217)

Ellen R. Gritz, Kathryn B. Arnold, Carol M. Moinpour, Allison M. Burton-Chase, Catherine M. Tangen, Jeffrey F. Probstfield, William A. See, Michael M. Lieber, Vincent Caggiano, Sarah Moody-Thomas, Connie Szczepanek, Anne Ryan, Susie Carlin, Shannon Hill, Phyllis J. Goodman, Rose Mary Padberg, Lori M. Minasian, Frank L. Meyskens, Ian M. Thompson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebocontrolled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6,13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P < 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P < 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials.

Original languageEnglish (US)
Pages (from-to)1638-1648
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Prostatic Neoplasms
Biopsy
Finasteride
Organized Financing
Prostate
Appointments and Schedules
Logistic Models
Health

ASJC Scopus subject areas

  • Oncology
  • Epidemiology

Cite this

Factors associated with adherence to an end-of-study biopsy : Lessons from the prostate cancer prevention trial (SWOG-coordinated intergroup study S9217). / Gritz, Ellen R.; Arnold, Kathryn B.; Moinpour, Carol M.; Burton-Chase, Allison M.; Tangen, Catherine M.; Probstfield, Jeffrey F.; See, William A.; Lieber, Michael M.; Caggiano, Vincent; Moody-Thomas, Sarah; Szczepanek, Connie; Ryan, Anne; Carlin, Susie; Hill, Shannon; Goodman, Phyllis J.; Padberg, Rose Mary; Minasian, Lori M.; Meyskens, Frank L.; Thompson, Ian M.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 8, 2014, p. 1638-1648.

Research output: Contribution to journalArticle

Gritz, ER, Arnold, KB, Moinpour, CM, Burton-Chase, AM, Tangen, CM, Probstfield, JF, See, WA, Lieber, MM, Caggiano, V, Moody-Thomas, S, Szczepanek, C, Ryan, A, Carlin, S, Hill, S, Goodman, PJ, Padberg, RM, Minasian, LM, Meyskens, FL & Thompson, IM 2014, 'Factors associated with adherence to an end-of-study biopsy: Lessons from the prostate cancer prevention trial (SWOG-coordinated intergroup study S9217)', Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 8, pp. 1638-1648. https://doi.org/10.1158/1055-9965.EPI-14-0202
Gritz, Ellen R. ; Arnold, Kathryn B. ; Moinpour, Carol M. ; Burton-Chase, Allison M. ; Tangen, Catherine M. ; Probstfield, Jeffrey F. ; See, William A. ; Lieber, Michael M. ; Caggiano, Vincent ; Moody-Thomas, Sarah ; Szczepanek, Connie ; Ryan, Anne ; Carlin, Susie ; Hill, Shannon ; Goodman, Phyllis J. ; Padberg, Rose Mary ; Minasian, Lori M. ; Meyskens, Frank L. ; Thompson, Ian M. / Factors associated with adherence to an end-of-study biopsy : Lessons from the prostate cancer prevention trial (SWOG-coordinated intergroup study S9217). In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 8. pp. 1638-1648.
@article{9c9b35ff7733421887513212ea8279ee,
title = "Factors associated with adherence to an end-of-study biopsy: Lessons from the prostate cancer prevention trial (SWOG-coordinated intergroup study S9217)",
abstract = "Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebocontrolled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6,13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P < 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P < 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials.",
author = "Gritz, {Ellen R.} and Arnold, {Kathryn B.} and Moinpour, {Carol M.} and Burton-Chase, {Allison M.} and Tangen, {Catherine M.} and Probstfield, {Jeffrey F.} and See, {William A.} and Lieber, {Michael M.} and Vincent Caggiano and Sarah Moody-Thomas and Connie Szczepanek and Anne Ryan and Susie Carlin and Shannon Hill and Goodman, {Phyllis J.} and Padberg, {Rose Mary} and Minasian, {Lori M.} and Meyskens, {Frank L.} and Thompson, {Ian M.}",
year = "2014",
doi = "10.1158/1055-9965.EPI-14-0202",
language = "English (US)",
volume = "23",
pages = "1638--1648",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Factors associated with adherence to an end-of-study biopsy

T2 - Lessons from the prostate cancer prevention trial (SWOG-coordinated intergroup study S9217)

AU - Gritz, Ellen R.

AU - Arnold, Kathryn B.

AU - Moinpour, Carol M.

AU - Burton-Chase, Allison M.

AU - Tangen, Catherine M.

AU - Probstfield, Jeffrey F.

AU - See, William A.

AU - Lieber, Michael M.

AU - Caggiano, Vincent

AU - Moody-Thomas, Sarah

AU - Szczepanek, Connie

AU - Ryan, Anne

AU - Carlin, Susie

AU - Hill, Shannon

AU - Goodman, Phyllis J.

AU - Padberg, Rose Mary

AU - Minasian, Lori M.

AU - Meyskens, Frank L.

AU - Thompson, Ian M.

PY - 2014

Y1 - 2014

N2 - Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebocontrolled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6,13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P < 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P < 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials.

AB - Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebocontrolled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6,13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P < 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P < 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials.

UR - http://www.scopus.com/inward/record.url?scp=84905455445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905455445&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0202

DO - 10.1158/1055-9965.EPI-14-0202

M3 - Article

C2 - 25028457

AN - SCOPUS:84905455445

VL - 23

SP - 1638

EP - 1648

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 8

ER -